Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2020)
Phathom Pharmaceuticals' (PHAT) quarterly Gains from Investment Securities came in at -$95000.0 in Q1 2020, down 100.26% on a QoQ basis from $37.2 million in Q4 2019.
Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2020) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Gains from Investment Securities data on file, last reported at -$95000.0 in Q1 2020.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to -$95000.0 in Q1 2020; TTM through Dec 2020 was -$95000.0, a N/A change from a year earlier, with the FY2020 full-year figure at -$95000.0, down 100.1% from the prior year.
- Gains from Investment Securities for Q1 2020 stood at -$95000.0, down from $37.2 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for PHAT reached as high as $57.8 million in Q3 2019 and fell as low as -$95000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Phathom Pharmaceuticals | 978.45 Mn | 794.69 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -95,000.00 |
| Mar 31, 2020 | -95,000.00 |
| Dec 31, 2019 | 37.21 Mn |
| Dec 31, 2019 | 37.21 Mn |
| Sep 30, 2019 | 57.78 Mn |
| Sep 30, 2019 | 57.78 Mn |
| Jun 30, 2019 | 1.28 Mn |
| Jun 30, 2019 | 1.28 Mn |